In the per-protocol analysis of first episodes of infections due to vaccine-type strains , community-acquired pneumonia occurred in 49 persons in the PCV13 group and 90 persons in the placebo group ( vaccine efficacy , 45.6 % ; 95.2 % confidence interval [ CI ] , 21.8 to 62.5 ) , nonbacteremic and noninvasive community-acquired pneumonia occurred in 33 persons in the PCV13 group and 60 persons in the placebo group ( vaccine efficacy , 45.0 % ; 95.2 % CI , 14.2 to 65.3 ) , and invasive pneumococcal disease occurred in 7 persons in the PCV13 group and 28 persons in the placebo group ( vaccine efficacy , 75.0 % ; 95 % CI , 41.4 to 90.8 ) .